MedTrace Logo

Next Generation Rocklatan

NCT06441643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 426

Last updated 2025-11-18

No results posted yet for this study

Summary

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

Interventions

DRUG

AR-17043 Ophthalmic Solution

Investigational monotherapy supplied in three concentration levels: low, medium, high

DRUG

PG043 Ophthalmic Solution

Investigational fixed dose combination supplied in two concentration levels: low and high

DRUG

Latanoprost 0.005% Ophthalmic Solution

Marketed monotherapy

DRUG

Netarsudil 0.02% Ophthalmic Solution

Marketed monotherapy

DRUG

Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution

Marketed fixed dose combination

DRUG

AR-17043 Vehicle

Placebo comparator

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Clinical Trial Lead, Pharma · Alcon Research, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-04
Primary Completion
2025-11-14
Completion
2025-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06441643 on ClinicalTrials.gov